Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-09-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924018072 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690907673100288 |
|---|---|
| author | Aurema Otero Elena Rosselló-Palmer Sergi Codina Nuria Lloberas Yurema Martínez Naiara Santos Judith Peñafiel Raúl Rigo-Bonnin Anna Vidal Joan Peris Sebastià Videla Miguel Hueso |
| author_facet | Aurema Otero Elena Rosselló-Palmer Sergi Codina Nuria Lloberas Yurema Martínez Naiara Santos Judith Peñafiel Raúl Rigo-Bonnin Anna Vidal Joan Peris Sebastià Videla Miguel Hueso |
| author_sort | Aurema Otero |
| collection | DOAJ |
| format | Article |
| id | doaj-art-14f989c42ce14f278d1cba899de78fe6 |
| institution | DOAJ |
| issn | 2468-0249 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj-art-14f989c42ce14f278d1cba899de78fe62025-08-20T03:21:11ZengElsevierKidney International Reports2468-02492024-09-01992798280210.1016/j.ekir.2024.06.030Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration PatientsAurema Otero0Elena Rosselló-Palmer1Sergi Codina2Nuria Lloberas3Yurema Martínez4Naiara Santos5Judith Peñafiel6Raúl Rigo-Bonnin7Anna Vidal8Joan Peris9Sebastià Videla10Miguel Hueso11Clinical Research Support Unit, Clinical Pharmacology Department, Hospital Universitari Bellvitge, L'Hospitalet del Llobregat, SpainThrombosis and Haemostasis Unit, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, SpainDepartment of Nephrology, Hospital Universitari de Bellvitge, Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, SpainExperimental Nephrology and Transplantation Laboratory, Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, SpainClinical Research Support Unit, Clinical Pharmacology Department, Hospital Universitari Bellvitge, L'Hospitalet del Llobregat, SpainBiostatistics Unit, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, SpainBiostatistics Unit, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, SpainClinical Laboratory Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, SpainExperimental Nephrology and Transplantation Laboratory, Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, SpainThrombosis and Haemostasis Unit, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, SpainClinical Research Support Unit, Clinical Pharmacology Department, Hospital Universitari Bellvitge, L'Hospitalet del Llobregat, Spain; Correspondence: Miguel Hueso, Department of Nephrology, Bellvitge University Hospital Nephrology Service L'Hospitalet de Llobregat, Barcelona, Spain; or Sebastià Videla, Clinical Research Support Unit, Clinical Pharmacology Department, Hospital Universitari Bellvitge and Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet del Llobregat, Spain.Department of Nephrology, Hospital Universitari de Bellvitge, Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; Experimental Nephrology and Transplantation Laboratory, Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; Correspondence: Miguel Hueso, Department of Nephrology, Bellvitge University Hospital Nephrology Service L'Hospitalet de Llobregat, Barcelona, Spain; or Sebastià Videla, Clinical Research Support Unit, Clinical Pharmacology Department, Hospital Universitari Bellvitge and Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet del Llobregat, Spain.http://www.sciencedirect.com/science/article/pii/S2468024924018072apixabandialysishemodiafiltrationpharmacodynamicspharmacokinetics |
| spellingShingle | Aurema Otero Elena Rosselló-Palmer Sergi Codina Nuria Lloberas Yurema Martínez Naiara Santos Judith Peñafiel Raúl Rigo-Bonnin Anna Vidal Joan Peris Sebastià Videla Miguel Hueso Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients Kidney International Reports apixaban dialysis hemodiafiltration pharmacodynamics pharmacokinetics |
| title | Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients |
| title_full | Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients |
| title_fullStr | Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients |
| title_full_unstemmed | Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients |
| title_short | Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients |
| title_sort | exploring apixaban pharmacokinetics pharmacodynamics and safety in hemodiafiltration patients |
| topic | apixaban dialysis hemodiafiltration pharmacodynamics pharmacokinetics |
| url | http://www.sciencedirect.com/science/article/pii/S2468024924018072 |
| work_keys_str_mv | AT auremaotero exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT elenarossellopalmer exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT sergicodina exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT nurialloberas exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT yuremamartinez exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT naiarasantos exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT judithpenafiel exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT raulrigobonnin exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT annavidal exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT joanperis exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT sebastiavidela exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients AT miguelhueso exploringapixabanpharmacokineticspharmacodynamicsandsafetyinhemodiafiltrationpatients |